PAVmed Newsroom

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow JonesDec 9 04:35 ET

PAVmed Analyst Ratings

BenzingaDec 9 04:25 ET

Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 16 07:32 ET

PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti

TipRanksNov 16 07:18 ET

Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Announces Target Price $4

Moomoo NewsSep 25 16:32 ET

Optimistic Buy Rating for PAVmed Amid Strategic Positioning and Promising Financial Outlook

TipRanksSep 25 15:35 ET

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow JonesSep 10 05:42 ET

PAVmed Analyst Ratings

BenzingaSep 10 05:32 ET

Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21

BenzingaSep 10 05:32 ET

Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating

Moomoo NewsAug 15 08:32 ET

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)

TipRanksMay 16 08:20 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)

TipRanksMay 15 15:45 ET

PAVmed (PAVM) Receives a Buy From Lake Street

TipRanksMay 15 09:05 ET

Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization

TipRanksApr 15 05:21 ET

Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

TipRanksMar 29 07:50 ET

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

TipRanksMar 28 09:25 ET

Cantor Fitzgerald Reiterates Neutral on PAVmed, Maintains $1.4 Price Target

BenzingaAug 18, 2023 10:46 ET

PAVmed Analyst Ratings

BenzingaAug 18, 2023 10:45 ET

PAVmed (PAVM) Receives a Buy From Maxim Group

TipRanksAug 18, 2023 07:45 ET

Maxim Group Remains a Buy on PAVmed (PAVM)

TipRanksMay 18, 2023 15:35 ET